Annual CFF
-$1.48 M
-$1.48 M-100.00%
December 31, 2023
Summary
- As of February 7, 2025, ATOS annual cash flow from financing activities is -$1.48 million, with the most recent change of -$1.48 million (-100.00%) on December 31, 2023.
- During the last 3 years, ATOS annual CFF has fallen by -$40.03 million (-103.83%).
- ATOS annual CFF is now -101.30% below its all-time high of $113.30 million, reached on December 31, 2021.
Performance
ATOS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$0.00
-$100.00 K-100.00%
September 30, 2024
Summary
- As of February 7, 2025, ATOS quarterly cash flow from financing activities is $0.00, with the most recent change of -$100.00 thousand (-100.00%) on September 30, 2024.
- Over the past year, ATOS quarterly CFF has increased by +$1.48 million (+100.00%).
- ATOS quarterly CFF is now -100.00% below its all-time high of $102.43 million, reached on March 31, 2021.
Performance
ATOS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$304.00 K
+$1.48 M+125.96%
September 30, 2024
Summary
- As of February 7, 2025, ATOS TTM cash flow from financing activities is $304.00 thousand, with the most recent change of +$1.48 million (+125.96%) on September 30, 2024.
- Over the past year, ATOS TTM CFF has increased by +$1.78 million (+120.61%).
- ATOS TTM CFF is now -99.80% below its all-time high of $150.83 million, reached on June 30, 2021.
Performance
ATOS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ATOS Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -100.0% | +100.0% | +120.6% |
| 3 y3 years | -103.8% | -100.0% | -99.8% |
| 5 y5 years | -112.0% | -100.0% | -99.8% |
ATOS Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -101.3% | at low | -100.0% | +100.0% | -99.7% | +120.6% |
| 5 y | 5-year | -101.3% | at low | -100.0% | +100.0% | -99.8% | +120.6% |
| alltime | all time | -101.3% | at low | -100.0% | +100.0% | -99.8% | +120.6% |
Atossa Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $0.00(-100.0%) | $304.00 K(-126.0%) |
| Jun 2024 | - | $100.00 K(-51.0%) | -$1.17 M(-7.9%) |
| Mar 2024 | - | $204.00 K(>+9900.0%) | -$1.27 M(-13.8%) |
| Dec 2023 | -$1.48 M(<-9900.0%) | $0.00(-100.0%) | -$1.48 M(0.0%) |
| Sep 2023 | - | -$1.48 M(<-9900.0%) | -$1.48 M(<-9900.0%) |
| Jun 2023 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2023 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2022 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Sep 2022 | - | $0.00(0.0%) | $1000.00(-99.9%) |
| Jun 2022 | - | $0.00(0.0%) | $680.00 K(-93.7%) |
| Mar 2022 | - | $0.00(-100.0%) | $10.88 M(-90.4%) |
| Dec 2021 | $113.30 M(+193.9%) | $1000.00(-99.9%) | $113.30 M(-23.0%) |
| Sep 2021 | - | $679.00 K(-93.3%) | $147.18 M(-2.4%) |
| Jun 2021 | - | $10.20 M(-90.0%) | $150.83 M(+7.0%) |
| Mar 2021 | - | $102.43 M(+202.3%) | $140.98 M(+265.7%) |
| Dec 2020 | $38.55 M(+240.1%) | $33.88 M(+683.5%) | $38.55 M(+725.2%) |
| Sep 2020 | - | $4.32 M(+1144.0%) | $4.67 M(+1244.0%) |
| Jun 2020 | - | $347.60 K(>+9900.0%) | $347.60 K(>+9900.0%) |
| Mar 2020 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Dec 2019 | $11.34 M(-7.8%) | $0.00(0.0%) | $11.34 M(0.0%) |
| Sep 2019 | - | $0.00(0.0%) | $11.34 M(0.0%) |
| Jun 2019 | - | $0.00(-100.0%) | $11.34 M(-52.0%) |
| Mar 2019 | - | $11.34 M(>+9900.0%) | $23.63 M(+92.2%) |
| Dec 2018 | $12.29 M(+14.0%) | $0.00(0.0%) | $12.29 M(-33.4%) |
| Sep 2018 | - | $0.00(-100.0%) | $18.46 M(-3.9%) |
| Jun 2018 | - | $12.29 M(+99.3%) | $19.20 M(+78.1%) |
| Dec 2017 | $10.78 M | $6.17 M(+727.4%) | $10.78 M(+133.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2017 | - | $745.30 K(-80.7%) | $4.62 M(-28.2%) |
| Jun 2017 | - | $3.87 M(>+9900.0%) | $6.43 M(+37.0%) |
| Dec 2016 | $4.70 M(-50.3%) | $0.00(-100.0%) | $4.70 M(-0.2%) |
| Sep 2016 | - | $2.56 M(-7958.6%) | $4.70 M(+125.3%) |
| Jun 2016 | - | -$32.60 K(-101.5%) | $2.09 M(-71.5%) |
| Mar 2016 | - | $2.17 M(>+9900.0%) | $7.33 M(-22.5%) |
| Dec 2015 | $9.46 M(-27.6%) | $7600.00(-114.1%) | $9.46 M(+1.1%) |
| Sep 2015 | - | -$53.90 K(-101.0%) | $9.35 M(-2.1%) |
| Jun 2015 | - | $5.21 M(+21.4%) | $9.55 M(+117.5%) |
| Mar 2015 | - | $4.29 M(-4457.7%) | $4.39 M(-66.3%) |
| Dec 2014 | $13.06 M(-6.3%) | -$98.50 K(-165.7%) | $13.06 M(-10.2%) |
| Sep 2014 | - | $150.00 K(+200.0%) | $14.54 M(-35.9%) |
| Jun 2014 | - | $50.00 K(-99.6%) | $22.69 M(-12.3%) |
| Mar 2014 | - | $12.96 M(+835.0%) | $25.89 M(+85.8%) |
| Dec 2013 | $13.94 M(+262.1%) | $1.39 M(-83.3%) | $13.94 M(-12.5%) |
| Sep 2013 | - | $8.30 M(+155.9%) | $15.92 M(+96.5%) |
| Jun 2013 | - | $3.25 M(+223.4%) | $8.10 M(+66.8%) |
| Mar 2013 | - | $1.00 M(-70.3%) | $4.86 M(+26.2%) |
| Dec 2012 | $3.85 M(-30.4%) | $3.37 M(+600.5%) | $3.85 M(+718.0%) |
| Sep 2012 | - | $481.60 K(>+9900.0%) | $470.50 K(-4338.7%) |
| Jun 2012 | - | $0.00(-100.0%) | -$11.10 K(-100.2%) |
| Mar 2012 | - | -$6200.00(+26.5%) | $5.52 M(-0.1%) |
| Dec 2011 | $5.53 M(+1847.1%) | -$4900.00(<-9900.0%) | $5.53 M(-0.1%) |
| Sep 2011 | - | $0.00(-100.0%) | $5.53 M(0.0%) |
| Jun 2011 | - | $5.53 M(>+9900.0%) | $5.53 M(>+9900.0%) |
| Mar 2011 | - | $0.00 | $0.00 |
| Dec 2010 | $284.00 K | - | - |
FAQ
- What is Atossa Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Atossa Therapeutics?
- What is Atossa Therapeutics annual CFF year-on-year change?
- What is Atossa Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Atossa Therapeutics?
- What is Atossa Therapeutics quarterly CFF year-on-year change?
- What is Atossa Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Atossa Therapeutics?
- What is Atossa Therapeutics TTM CFF year-on-year change?
What is Atossa Therapeutics annual cash flow from financing activities?
The current annual CFF of ATOS is -$1.48 M
What is the all time high annual CFF for Atossa Therapeutics?
Atossa Therapeutics all-time high annual cash flow from financing activities is $113.30 M
What is Atossa Therapeutics annual CFF year-on-year change?
Over the past year, ATOS annual cash flow from financing activities has changed by -$1.48 M (-100.00%)
What is Atossa Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of ATOS is $0.00
What is the all time high quarterly CFF for Atossa Therapeutics?
Atossa Therapeutics all-time high quarterly cash flow from financing activities is $102.43 M
What is Atossa Therapeutics quarterly CFF year-on-year change?
Over the past year, ATOS quarterly cash flow from financing activities has changed by +$1.48 M (+100.00%)
What is Atossa Therapeutics TTM cash flow from financing activities?
The current TTM CFF of ATOS is $304.00 K
What is the all time high TTM CFF for Atossa Therapeutics?
Atossa Therapeutics all-time high TTM cash flow from financing activities is $150.83 M
What is Atossa Therapeutics TTM CFF year-on-year change?
Over the past year, ATOS TTM cash flow from financing activities has changed by +$1.78 M (+120.61%)